Table 5.
Interactions between nonsteroidal anti-inflammatory drug (NSAID) use and MDR1, COX-2 and BCRP polymorphisms.
| Polymorphism | Ncase/Nsub-cohort | IRRa (95% CI) | IRRb (95% CI) | p-valuec | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NSAIDd | NSAIDd | NSAIDd | |||||||||
| NO | YES | NO | YES | NO | YES | ||||||
| MDR1 C3435T | |||||||||||
| CC | 41/79 | 32/39 | 1.00 | - | 2.21 | (1.17-4.17) | 1.00 | - | 2.34 | (1.22-4.48) | 0.001 |
| CT and TT | 204/449 | 82/198 | 0.92 | (0.60-1.41) | 0.83 | (0.52-1.33) | 0.99 | (0.63-1.54) | 0.86 | (0.53-1.39) | |
| MDR1 G-rs 3789243-A | |||||||||||
| GG | 54/160 | 27/64 | 1.00 | - | 1.35 | (0.77-2.35) | 1.00 | - | 1.31 | (0.74-2.32) | 0.26 |
| GA and AA | 191/368 | 87/173 | 1.65 | (1.15-2.38) | 1.65 | (1.09-2.49) | 1.66 | (1.15-2.41) | 1.61 | (1.06-2.46) | |
| COX-2 G-765C | |||||||||||
| GG | 180/397 | 87/169 | 1.00 | - | 1.22 | (0.89-1.69) | 1.00 | - | 1.20 | (0.86-1.67) | 0.06 |
| CG and CC | 65/131 | 27/68 | 1.22 | (0.86-1.75) | 0.93 | (0.57-1.51) | 1.23 | (0.85-1.78) | 0.90 | (0.54-1.48) | |
| COX-2 A-1195G | |||||||||||
| AA | 156/329 | 74/153 | 1.00 | - | 1.05 | (0.75-1.48) | 1.00 | - | 0.99 | (0.69-1.41) | 0.46 |
| AG and GG | 89/199 | 40/84 | 0.91 | (0.66-1.27) | 1.04 | (0.67-1.60) | 0.88 | (0.63-1.23) | 1.04 | (0.67-1.61) | |
| COX-2 T8473C | |||||||||||
| TT | 94/222 | 53/93 | 1.00 | - | 1.42 | (0.92-2.18) | 1.00 | - | 1.38 | (0.89-2.14) | 0.04 |
| CT and CC | 151/306 | 61/144 | 1.23 | (0.89-1.70) | 1.09 | (0.73-1.62) | 1.22 | (0.87-1.69) | 1.05 | (0.70-1.58) | |
| BCRP C421A | |||||||||||
| CC | 199/414 | 97/178 | 1.00 | - | 1.20 | (0.88-1.63) | 1.00 | - | 1.18 | (0.85-1.62) | 0.09 |
| CA and AA | 46/114 | 17/59 | 0.86 | (0.58-1.27) | 0.62 | (0.35-1.10) | 0.86 | (0.57-1.29) | 0.60 | (0.33-1.08) | |
aCrude (adjusted for age and sex).
bAdjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, red meat and BMI.
cp-value for interaction for the fully adjusted risk estimates.
dStudy subjects were classified according to use of "any NSAID" (≥ 2 pills per month during one year) at baseline